

Table 1.18

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Both Sexes, Total U.S., 2011-2013

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 20.41 (20.38, 20.44) | 20.52 (20.49, 20.55) | 20.77 (20.68, 20.86) |
| Oral Cavity and Pharynx | 0.29 (0.28, 0.29) | 0.29 (0.28, 0.29) | 0.29 (0.28, 0.30) |
| Esophagus | 0.48 (0.48, 0.49) | 0.51 (0.50, 0.51) | 0.37 (0.36, 0.39) |
| Stomach | 0.39 (0.38, 0.39) | 0.34 (0.34, 0.34) | 0.64 (0.62, 0.66) |
| Colon and Rectum | 1.85 (1.84, 1.86) | 1.81 (1.80, 1.82) | 2.18 (2.15, 2.22) |
| Liver and Intrahepatic Bile Duct | 0.73 (0.72, 0.74) | 0.69 (0.68, 0.69) | 0.84 (0.82, 0.86) |
| Pancreas | 1.35 (1.35, 1.36) | 1.35 (1.34, 1.36) | 1.45 (1.43, 1.48) |
| Larynx | 0.12 (0.12, 0.12) | 0.12 (0.11, 0.12) | 0.18 (0.17, 0.19) |
| Lung and Bronchus | 5.43 (5.41, 5.45) | 5.54 (5.53, 5.56) | 5.07 (5.02, 5.12) |
| Melanoma of the Skin | 0.31 (0.31, 0.32) | 0.36 (0.36, 0.36) | 0.04 (0.04, 0.05) |
| Breast | 1.39 (1.38, 1.40) | 1.36 (1.35, 1.37) | 1.75 (1.73, 1.78) |
| Urinary Bladder | 0.61 (0.61, 0.62) | 0.64 (0.64, 0.65) | 0.42 (0.41, 0.44) |
| Kidney and Renal Pelvis | 0.47 (0.47, 0.48) | 0.49 (0.48, 0.49) | 0.39 (0.37, 0.40) |
| Brain and Other Nervous System | 0.46 (0.45, 0.46) | 0.50 (0.50, 0.51) | 0.24 (0.23, 0.25) |
| Thyroid | 0.06 (0.06, 0.06) | 0.06 (0.06, 0.06) | 0.05 (0.05, 0.06) |
| Hodgkin Lymphoma | 0.04 (0.03, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.02, 0.03) |
| Non-Hodgkin Lymphoma | 0.75 (0.75, 0.76) | 0.79 (0.79, 0.80) | 0.44 (0.43, 0.46) |
| Myeloma | 0.43 (0.42, 0.43) | 0.40 (0.40, 0.41) | 0.69 (0.67, 0.71) |
| Leukemia | 0.86 (0.85, 0.87) | 0.90 (0.89, 0.90) | 0.62 (0.60, 0.64) |
| Acute Lymphocytic Leukemia | 0.04 (0.04, 0.04) | 0.04 (0.04, 0.05) | 0.03 (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.19 (0.19, 0.19) | 0.20 (0.19, 0.20) | 0.14 (0.13, 0.15) |
| Acute Myeloid Leukemia | 0.33 (0.33, 0.34) | 0.35 (0.34, 0.35) | 0.22 (0.21, 0.23) |
| Chronic Myeloid Leukemia | 0.04 (0.04, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.03, 0.04) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2011-2013

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 18.26 (18.04, 18.48) | 16.78 (16.31, 17.27) | 17.57 (17.43, 17.71) |
| Oral Cavity and Pharynx | 0.30 (0.27, 0.33) | 0.21 (0.16, 0.29) | 0.21 (0.20, 0.23) |
| Esophagus | 0.29 (0.26, 0.33) | 0.34 (0.28, 0.43) | 0.32 (0.30, 0.34) |
| Stomach | 1.01 (0.95, 1.07) | 0.59 (0.50, 0.71) | 0.75 (0.72, 0.78) |
| Colon and Rectum | 1.91 (1.83, 1.99) | 1.91 (1.73, 2.12) | 1.86 (1.81, 1.92) |
| Liver and Intrahepatic Bile Duct | 1.57 (1.51, 1.63) | 1.10 (0.99, 1.24) | 1.27 (1.23, 1.30) |
| Pancreas | 1.43 (1.36, 1.49) | 1.01 (0.89, 1.16) | 1.32 (1.28, 1.36) |
| Larynx | 0.07 (0.05, 0.09) | 0.07 (0.04, 0.13) | 0.11 (0.10, 0.13) |
| Lung and Bronchus | 4.23 (4.12, 4.34) | 4.11 (3.87, 4.36) | 2.93 (2.88, 2.99) |
| Melanoma of the Skin | 0.05 (0.04, 0.07) | 0.10 (0.06, 0.18) | 0.11 (0.10, 0.12) |
| Breast | 0.96 (0.90, 1.01) | 0.88 (0.77, 1.03) | 1.13 (1.09, 1.17) |
| Urinary Bladder | 0.42 (0.37, 0.46) | 0.26 (0.20, 0.37) | 0.44 (0.41, 0.47) |
| Kidney and Renal Pelvis | 0.34 (0.30, 0.38) | 0.71 (0.60, 0.84) | 0.50 (0.48, 0.53) |
| Brain and Other Nervous System | 0.27 (0.24, 0.29) | 0.22 (0.17, 0.29) | 0.36 (0.34, 0.37) |
| Thyroid | 0.12 (0.10, 0.14) | 0.08 (0.04, 0.17) | 0.09 (0.08, 0.10) |
| Hodgkin Lymphoma | 0.03 (0.02, 0.04) | 0.02 (0.01, 0.08) | 0.05 (0.05, 0.06) |
| Non-Hodgkin Lymphoma | 0.73 (0.69, 0.79) | 0.49 (0.41, 0.61) | 0.76 (0.73, 0.79) |
| Myeloma | 0.29 (0.26, 0.32) | 0.31 (0.25, 0.41) | 0.42 (0.40, 0.44) |
| Leukemia | 0.65 (0.61, 0.69) | 0.49 (0.40, 0.61) | 0.69 (0.67, 0.72) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.05) | 0.03 (0.02, 0.09) | 0.07 (0.06, 0.08) |
| Chronic Lymphocytic Leukemia | 0.05 (0.04, 0.07) | 0.09 (0.05, 0.17) | 0.09 (0.08, 0.11) |
| Acute Myeloid Leukemia | 0.33 (0.30, 0.36) | 0.21 (0.15, 0.30) | 0.25 (0.24, 0.27) |
| Chronic Myeloid Leukemia | 0.03 (0.02, 0.05) | 0.01 (0.01, 0.07) | 0.04 (0.03, 0.04) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2011-2013

| Site | All Races | | Whites | | Blacks | |
|----------------------------------|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 22.28 | (22.24, 22.33) | 22.35 | (22.30, 22.39) | 22.97 | (22.83, 23.11) |
| Oral Cavity and Pharynx | 0.40 | (0.39, 0.40) | 0.39 | (0.39, 0.40) | 0.45 | (0.43, 0.47) |
| Esophagus | 0.78 | (0.77, 0.79) | 0.82 | (0.81, 0.83) | 0.56 | (0.53, 0.58) |
| Stomach | 0.47 | (0.46, 0.48) | 0.41 | (0.41, 0.42) | 0.78 | (0.75, 0.81) |
| Colon and Rectum | 1.94 | (1.93, 1.96) | 1.90 | (1.88, 1.92) | 2.34 | (2.29, 2.39) |
| Liver and Intrahepatic Bile Duct | 0.97 | (0.96, 0.98) | 0.90 | (0.89, 0.91) | 1.18 | (1.15, 1.22) |
| Pancreas | 1.37 | (1.36, 1.38) | 1.38 | (1.37, 1.39) | 1.35 | (1.31, 1.39) |
| Larynx | 0.20 | (0.19, 0.20) | 0.19 | (0.18, 0.19) | 0.31 | (0.29, 0.33) |
| Lung and Bronchus | 6.14 | (6.12, 6.17) | 6.19 | (6.17, 6.22) | 6.24 | (6.16, 6.32) |
| Melanoma of the Skin | 0.43 | (0.42, 0.44) | 0.49 | (0.48, 0.50) | 0.04 | (0.03, 0.05) |
| Breast | 0.03 | (0.03, 0.03) | 0.03 | (0.03, 0.03) | 0.04 | (0.04, 0.05) |
| Prostate | 2.50 | (2.48, 2.51) | 2.33 | (2.32, 2.35) | 4.23 | (4.15, 4.31) |
| Testis | 0.02 | (0.02, 0.02) | 0.02 | (0.02, 0.02) | 0.01 | (0.01, 0.01) |
| Urinary Bladder | 0.93 | (0.92, 0.94) | 0.99 | (0.97, 1.00) | 0.52 | (0.50, 0.55) |
| Kidney and Renal Pelvis | 0.61 | (0.61, 0.62) | 0.64 | (0.63, 0.64) | 0.50 | (0.48, 0.52) |
| Brain and Other Nervous System | 0.52 | (0.51, 0.52) | 0.56 | (0.55, 0.57) | 0.27 | (0.25, 0.29) |
| Thyroid | 0.06 | (0.05, 0.06) | 0.06 | (0.06, 0.06) | 0.03 | (0.03, 0.04) |
| Hodgkin Lymphoma | 0.04 | (0.04, 0.04) | 0.04 | (0.04, 0.05) | 0.03 | (0.03, 0.04) |
| Non-Hodgkin Lymphoma | 0.86 | (0.85, 0.87) | 0.90 | (0.89, 0.91) | 0.49 | (0.47, 0.51) |
| Myeloma | 0.48 | (0.47, 0.48) | 0.46 | (0.45, 0.47) | 0.68 | (0.66, 0.71) |
| Leukemia | 1.03 | (1.02, 1.04) | 1.07 | (1.06, 1.09) | 0.69 | (0.67, 0.72) |
| Acute Lymphocytic Leukemia | 0.05 | (0.04, 0.05) | 0.05 | (0.05, 0.05) | 0.03 | (0.03, 0.04) |
| Chronic Lymphocytic Leukemia | 0.24 | (0.23, 0.24) | 0.25 | (0.24, 0.25) | 0.17 | (0.15, 0.18) |
| Acute Myeloid Leukemia | 0.40 | (0.39, 0.40) | 0.41 | (0.41, 0.42) | 0.24 | (0.23, 0.26) |
| Chronic Myeloid Leukemia | 0.04 | (0.04, 0.05) | 0.05 | (0.04, 0.05) | 0.03 | (0.03, 0.04) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Males, Total U.S., 2011-2013

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 20.60 (20.26, 20.95) | 17.79 (17.09, 18.56) | 19.93 (19.71, 20.16) |
| Oral Cavity and Pharynx | 0.40 (0.35, 0.46) | 0.34 (0.25, 0.54) | 0.29 (0.26, 0.32) |
| Esophagus | 0.45 (0.40, 0.52) | 0.46 (0.36, 0.66) | 0.53 (0.50, 0.58) |
| Stomach | 1.19 (1.10, 1.29) | 0.73 (0.57, 0.99) | 0.91 (0.86, 0.97) |
| Colon and Rectum | 2.05 (1.94, 2.18) | 1.82 (1.60, 2.12) | 2.10 (2.02, 2.18) |
| Liver and Intrahepatic Bile Duct | 2.06 (1.96, 2.18) | 1.35 (1.18, 1.60) | 1.63 (1.58, 1.70) |
| Pancreas | 1.40 (1.30, 1.50) | 0.91 (0.76, 1.15) | 1.27 (1.21, 1.33) |
| Larynx | 0.13 (0.11, 0.17) | 0.10 (0.06, 0.28) | 0.21 (0.19, 0.24) |
| Lung and Bronchus | 5.27 (5.10, 5.45) | 4.57 (4.19, 5.01) | 3.78 (3.69, 3.89) |
| Melanoma of the Skin | 0.06 (0.05, 0.10) | 0.11 (0.06, 0.28) | 0.14 (0.12, 0.17) |
| Breast | 0.02 (0.01, 0.05) | 0.02 (0.00, 0.19) | 0.02 (0.01, 0.04) |
| Prostate | 2.10 (1.95, 2.26) | 2.06 (1.77, 2.43) | 2.91 (2.80, 3.03) |
| Testis | 0.01 (0.00, 0.03) | 0.02 (0.01, 0.19) | 0.02 (0.02, 0.03) |
| Urinary Bladder | 0.64 (0.56, 0.73) | 0.45 (0.29, 0.71) | 0.68 (0.62, 0.74) |
| Kidney and Renal Pelvis | 0.44 (0.39, 0.51) | 0.82 (0.67, 1.07) | 0.63 (0.59, 0.68) |
| Brain and Other Nervous System | 0.29 (0.26, 0.34) | 0.26 (0.20, 0.43) | 0.37 (0.35, 0.40) |
| Thyroid | 0.09 (0.07, 0.13) | 0.07 (0.03, 0.24) | 0.06 (0.05, 0.08) |
| Hodgkin Lymphoma | 0.03 (0.02, 0.06) | 0.03 (0.01, 0.20) | 0.07 (0.06, 0.08) |
| Non-Hodgkin Lymphoma | 0.84 (0.77, 0.93) | 0.60 (0.45, 0.85) | 0.85 (0.81, 0.91) |
| Myeloma | 0.33 (0.29, 0.38) | 0.33 (0.24, 0.54) | 0.46 (0.42, 0.50) |
| Leukemia | 0.78 (0.71, 0.86) | 0.56 (0.41, 0.80) | 0.82 (0.78, 0.87) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.07) | 0.04 (0.02, 0.21) | 0.08 (0.07, 0.10) |
| Chronic Lymphocytic Leukemia | 0.07 (0.05, 0.11) | 0.16 (0.07, 0.38) | 0.12 (0.10, 0.15) |
| Acute Myeloid Leukemia | 0.40 (0.35, 0.45) | 0.19 (0.13, 0.37) | 0.29 (0.27, 0.32) |
| Chronic Myeloid Leukemia | 0.03 (0.02, 0.06) | 0.02 (0.01, 0.20) | 0.04 (0.03, 0.05) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.20

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2011-2013

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 18.90 (18.86, 18.93) | 19.02 (18.98, 19.06) | 19.21 (19.09, 19.33) |
| Oral Cavity and Pharynx | 0.18 (0.18, 0.18) | 0.18 (0.18, 0.19) | 0.15 (0.14, 0.17) |
| Esophagus | 0.20 (0.20, 0.21) | 0.20 (0.20, 0.21) | 0.22 (0.20, 0.23) |
| Stomach | 0.31 (0.31, 0.32) | 0.27 (0.27, 0.28) | 0.53 (0.50, 0.55) |
| Colon and Rectum | 1.77 (1.76, 1.78) | 1.73 (1.72, 1.75) | 2.06 (2.02, 2.11) |
| Liver and Intrahepatic Bile Duct | 0.50 (0.49, 0.51) | 0.47 (0.47, 0.48) | 0.53 (0.51, 0.56) |
| Pancreas | 1.34 (1.33, 1.35) | 1.32 (1.30, 1.33) | 1.54 (1.50, 1.58) |
| Larynx | 0.05 (0.05, 0.05) | 0.05 (0.05, 0.05) | 0.06 (0.06, 0.07) |
| Lung and Bronchus | 4.80 (4.78, 4.82) | 4.97 (4.95, 4.99) | 4.11 (4.05, 4.17) |
| Melanoma of the Skin | 0.21 (0.20, 0.21) | 0.24 (0.23, 0.24) | 0.04 (0.04, 0.05) |
| Breast | 2.65 (2.63, 2.66) | 2.61 (2.60, 2.63) | 3.22 (3.17, 3.27) |
| Cervix Uteri | 0.23 (0.22, 0.23) | 0.21 (0.20, 0.21) | 0.38 (0.36, 0.40) |
| Corpus and Uterus, NOS | 0.59 (0.58, 0.60) | 0.55 (0.54, 0.56) | 0.96 (0.93, 0.99) |
| Ovary | 0.94 (0.93, 0.95) | 0.98 (0.97, 0.99) | 0.74 (0.72, 0.77) |
| Urinary Bladder | 0.34 (0.34, 0.35) | 0.35 (0.34, 0.35) | 0.35 (0.33, 0.37) |
| Kidney and Renal Pelvis | 0.34 (0.34, 0.35) | 0.35 (0.35, 0.36) | 0.30 (0.28, 0.31) |
| Brain and Other Nervous System | 0.41 (0.40, 0.41) | 0.44 (0.44, 0.45) | 0.21 (0.20, 0.22) |
| Thyroid | 0.07 (0.07, 0.07) | 0.07 (0.06, 0.07) | 0.07 (0.06, 0.08) |
| Hodgkin Lymphoma | 0.03 (0.03, 0.03) | 0.03 (0.03, 0.03) | 0.02 (0.02, 0.03) |
| Non-Hodgkin Lymphoma | 0.67 (0.66, 0.68) | 0.70 (0.69, 0.71) | 0.41 (0.39, 0.43) |
| Myeloma | 0.39 (0.38, 0.39) | 0.35 (0.35, 0.36) | 0.69 (0.67, 0.72) |
| Leukemia | 0.72 (0.71, 0.72) | 0.74 (0.73, 0.75) | 0.56 (0.54, 0.58) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.15 (0.14, 0.15) | 0.16 (0.15, 0.16) | 0.12 (0.10, 0.13) |
| Acute Myeloid Leukemia | 0.28 (0.27, 0.28) | 0.29 (0.28, 0.30) | 0.20 (0.19, 0.22) |
| Chronic Myeloid Leukemia | 0.03 (0.03, 0.04) | 0.03 (0.03, 0.04) | 0.03 (0.03, 0.04) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.20 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2011-2013

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 16.45 (16.17, 16.74) | 15.99 (15.35, 16.67) | 15.85 (15.68, 16.03) |
| Oral Cavity and Pharynx | 0.22 (0.18, 0.26) | 0.09 (0.05, 0.20) | 0.14 (0.13, 0.17) |
| Esophagus | 0.16 (0.13, 0.20) | 0.22 (0.15, 0.36) | 0.14 (0.12, 0.16) |
| Stomach | 0.86 (0.79, 0.95) | 0.47 (0.36, 0.64) | 0.62 (0.59, 0.66) |
| Colon and Rectum | 1.79 (1.69, 1.90) | 1.96 (1.70, 2.28) | 1.67 (1.61, 1.74) |
| Liver and Intrahepatic Bile Duct | 1.15 (1.08, 1.24) | 0.86 (0.72, 1.06) | 0.94 (0.90, 0.99) |
| Pancreas | 1.45 (1.37, 1.55) | 1.09 (0.91, 1.33) | 1.36 (1.30, 1.42) |
| Larynx | 0.02 (0.01, 0.04) | 0.03 (0.01, 0.14) | 0.03 (0.02, 0.04) |
| Lung and Bronchus | 3.40 (3.27, 3.54) | 3.74 (3.44, 4.08) | 2.25 (2.18, 2.32) |
| Melanoma of the Skin | 0.05 (0.03, 0.07) | 0.09 (0.03, 0.22) | 0.09 (0.08, 0.10) |
| Breast | 1.73 (1.63, 1.83) | 1.70 (1.48, 1.96) | 2.09 (2.02, 2.15) |
| Cervix Uteri | 0.25 (0.22, 0.29) | 0.27 (0.20, 0.39) | 0.30 (0.28, 0.32) |
| Corpus and Uterus, NOS | 0.46 (0.41, 0.51) | 0.44 (0.35, 0.59) | 0.55 (0.52, 0.58) |
| Ovary | 0.67 (0.62, 0.73) | 0.73 (0.60, 0.91) | 0.81 (0.77, 0.85) |
| Urinary Bladder | 0.24 (0.20, 0.30) | 0.12 (0.08, 0.24) | 0.26 (0.23, 0.29) |
| Kidney and Renal Pelvis | 0.25 (0.21, 0.30) | 0.59 (0.46, 0.79) | 0.39 (0.36, 0.42) |
| Brain and Other Nervous System | 0.24 (0.21, 0.28) | 0.17 (0.12, 0.29) | 0.34 (0.31, 0.36) |
| Thyroid | 0.14 (0.11, 0.17) | 0.10 (0.04, 0.23) | 0.11 (0.09, 0.13) |
| Hodgkin Lymphoma | 0.02 (0.01, 0.05) | 0.01 (0.00, 0.11) | 0.04 (0.04, 0.05) |
| Non-Hodgkin Lymphoma | 0.65 (0.59, 0.72) | 0.41 (0.30, 0.57) | 0.68 (0.65, 0.72) |
| Myeloma | 0.25 (0.22, 0.29) | 0.30 (0.22, 0.44) | 0.39 (0.36, 0.42) |
| Leukemia | 0.54 (0.49, 0.60) | 0.43 (0.32, 0.61) | 0.60 (0.56, 0.63) |
| Acute Lymphocytic Leukemia | 0.03 (0.02, 0.05) | 0.03 (0.01, 0.13) | 0.06 (0.05, 0.07) |
| Chronic Lymphocytic Leukemia | 0.04 (0.02, 0.06) | 0.03 (0.01, 0.14) | 0.07 (0.06, 0.09) |
| Acute Myeloid Leukemia | 0.28 (0.24, 0.32) | 0.22 (0.14, 0.36) | 0.22 (0.20, 0.24) |
| Chronic Myeloid Leukemia | 0.03 (0.02, 0.06) | 0.00 (0.00, 0.11) | 0.04 (0.03, 0.05) |

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.